Evidence map›Paper›PMID 29699816›Full record

Trial reportNutrition, metabolism, and cardiovascular diseases : NMCD2018

Weight gain prevention buffers the impact of CETP rs3764261 on high density lipoprotein cholesterol in young adulthood: The Study of Novel Approaches to Weight Gain Prevention (SNAP).

J M McCaffery, J M Ordovas, G S Huggins, C-Q Lai, M A Espeland, D F Tate, R R Wing

Registry-linked trialAbstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in Nutrition, metabolism, and cardiovascular diseases : NMCD, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01183689 (Study of Novel Approaches for Prevention), which is not on this map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.5field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01183689 nacompletednot on this map

Study of Novel Approaches for Prevention

TypeinterventionalSponsorWake Forest UniversityRan2010 to 2018Enrolled599ConditionsWeight GainArmsSmall Behavior Changes, Large Behavior Changes
3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. CETP gene polymorphisms and haplotypes are explanatory variables for HDL cholesterol level in sickle cell disease.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2024
    Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Association ofPharmacogenomics and personalized medicine · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

J M McCafferyDepartment of Psychiatry and Human Behavior, Alpert School of Medicine at Brown University, USA. Electronic address: jeanne.mccaffery@uconn.edu.
J M OrdovasJM-USDA-HNRCA at Tufts University, USA; IMDEA Alimentacion, Madrid, Spain.
G S HugginsSackler School of Biomedical Science, Tufts University, Madrid, Spain.
C-Q LaiUSDA-ARS, JM-USDA Human Nutrition Research Center on Aging at Tufts University, USA.
M A EspelandDepartment of Biostatistical Sciences, Wake Forest School of Medicine, USA.
D F TateGillings School of Global Public Health, University of North Carolina, Carolina, USA.
R R WingDepartment of Psychiatry and Human Behavior, Alpert School of Medicine at Brown University, USA.
Brown University · USTufts University · USWake Forest University · US

Funding

Carolina Population CenterR24HD050924 · NICHD · UNIV OF NORTH CAROLINA CHAPEL HILL · PI MORGAN, SAMUEL PHILIP · 2005 to 2014
$10.0M
Prevention of Weight Gain in Young AdultsU01HL090864 · NHLBI · MIRIAM HOSPITAL · PI WING, RENA R · 2009 to 2014
$5.8M
NHLBI NIH HHS U01 HL090864NICHD NIH HHS R24 HD050924
6 · The paper itself

Abstract

BACKGROUND AND

aimsTwo weight gain prevention strategies, one targeting small changes to diet and physical activity and a second targeting large changes, significantly reduced weight gain in young adulthood. We examined whether weight gain prevention blunts genetic risk for body weight increase and/or high density lipoprotein cholesterol (HDL-C) lowering over two years. METHODS AND

resultsParticipants were 524 male and female young adults (mean age = 28.2, SD = 4.3; mean BMI = 25.5, SD = 2.6). Obesity-related SNPs accounting for ≥ 0.04% of the variance were genotyped and combined into a genetic risk score. For HDL-C, SNPs within CETP, LIPC and FADS2 were genotyped. The obesity-related genetic risk score did not predict change in BMI independently or in interaction with treatment arm. However, consistent with the prior literature, each copy of the HDL-C risk, C, allele at CETP rs3764261 was associated with lower HDL-C at baseline. Moreover, significant interaction between SNP and treatment arm for change in HDL-C was observed (p = 0.02). In the control group, HDL-C change was dependent upon rs3764261 (p = 0.004) with C allele carriers showing a continued reduction in HDL-C. In contrast, within the two intervention groups, HDL-C increased on average with no differential effect of rs3764261 (p > 0.24). Notably, even among carriers of the CC genotype, small and large change arms were associated with increased HDL-C and the control arm a reduction (p = 0.013).

conclusionsThe C allele at CETP rs3764261 is a strong risk factor for low HDL-C in young adulthood but weight gain prevention may mitigate this risk. CLINICAL TRIAL REGISTRY NUMBER AND WEBSITE: clinicaltrials.gov Identifier: NCT01183689, https://clinicaltrials.gov/.

Indexed as

Polymorphism, Single NucleotideAdolescentAdultAge FactorsBiomarkersBody Mass IndexCholesterol Ester Transfer ProteinsCholesterol, HDLDyslipidemiasFemaleGenetic Predisposition to DiseaseGenome-Wide Association StudyHumansMaleObesityPhenotypeBiomarkersCETP protein, humanCholesterol Ester Transfer ProteinsCholesterol, HDLBody mass indexGeneticsHigh-density lipoprotein cholesterolPreventionYoung adulthood

Identifiers

PMID29699816
PMCPMC6127000
OpenAlexW2793981556

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.